Phase I/II study assessing radioligand therapy (RLT) using 177Lu-PentixaTher for relapsed/refractory CXCR4+ acute leukemia.

2022-501019-15-00 Protocol RC20_0123 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 22 Oct 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 8 sites · Protocol RC20_0123

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 21
Countries 1
Sites 8

Acute Leukemia

Key facts

Sponsor
Centre Hospitalier Universitaire De Nantes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
Trial duration
22 Oct 2024 → ongoing
Decision date (initial)
2024-03-25
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-501019-15-00
ClinicalTrials.gov
NCT06356922

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Acute Leukemia

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nantes

Sponsor organisation
Centre Hospitalier Universitaire De Nantes
Address
1 Place Alexis Ricordeau
City
Nantes
Postcode
44000
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Pr Patrice CHEVALLIER

Public contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Pr Patrice CHEVALLIER

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 21 8
Rest of world 0

Investigational sites

France

8 sites · Ongoing, recruiting
Centre Hospitalier Universitaire De Nantes
Médecine Nucleaire, 5 Allee De L Ile Gloriette, Cs 69301, Nantes Cedex 1
University Hospital Of Clermont-Ferrand
Hématologie, 1 Place Lucie Et Raymond Aubrac, 63100, Clermont-Ferrand
Centre Hospitalier Universitaire D'Angers
Hématologie, 4 Rue Larrey, 49100, Angers
University Hospital Of Clermont-Ferrand
Médecine Nucleaire, 58 Rue Montalembert, 63003, Clermont Ferrand Cedex 1
Centre Hospitalier Universitaire De Bordeaux
Hématologie, Avenue De Magellan, 33600, Pessac
Centre Hospitalier Universitaire De Nantes
Hématologie, 5 Allee De L Ile Gloriette, Cs 69301, Nantes Cedex 1
Centre Hospitalier Universitaire D'Angers
Médecine Nucleaire, 4 Rue Larrey, 49100, Angers
Centre Hospitalier Universitaire De Bordeaux
Médecine Nucleaire, Avenue De Magellan, 33600, Pessac

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-10-22 2024-10-22

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-21 France Acceptable
2024-03-25
2024-03-25
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-02 France Acceptable
2024-07-25
2024-07-25
3 SUBSTANTIAL MODIFICATION SM-2 2025-01-21 France Acceptable
2025-02-18
2025-02-19
4 SUBSTANTIAL MODIFICATION SM-3 2025-07-02 France Acceptable
2025-07-22
2025-08-12
5 SUBSTANTIAL MODIFICATION SM-4 2025-10-20 France Acceptable
2025-12-18
2025-12-18
6 NON SUBSTANTIAL MODIFICATION NSM-1 2026-04-15 France Acceptable
2025-12-18
2026-04-15